Spondyloarthritis & psoriatic arthritis
Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now?
Authors' conclusion
Many challenges remain, but the anticipated results of studies being conducted by recently established large consortia may lead to the identification of clinically actionable biomarkers.
Study context
- Population
- Psoriatic disease (PsD): psoriasis and PsA
- Outcome
- Status of PsD biomarkers
Methodological detailsGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual conference workshop
- GRAPPA 2023 annual conference workshop
Main finding
As reported in the abstract
- A few potential biomarkers discovered, none fully validated
- Omic technologies show promise but need further verification and validation
Original publication
Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now? J Rheumatol. Published 15 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →